52daqing 论坛,为全国人民代表(网名认证: "大庆家德帝", 请勿与"北京庆丰帝"弄混)所运营 - 通过执法, 产品与服务改变中国,社会, 为公众创造健康, 幸福, 安全与和谐的工作生活环境. 5秒注册, 匿名访问, 自由表达, 不受限. 我们的口号是: 有实力, 更有战绩. 我们主要擅长以人民, 习主席,法律, 美军,外星人的名义公开打击党员犯罪,专啃硬骨头. 关于本站读者群体的实力? 请先了解一下AlienPuppyHawaii.com的业务领域和读者, 例如TRUMP总统和CIA的实力.干细胞治疗这些病症, 我们叫CONDITIONS, SYMPTOM(而不是病 …回复帖子

回复帖子: 这些病症, 我们叫CONDITIONS, SYMPTOM(而不是病),日本正在临床测试,很多八字没一撇

<blockquote><div class="quotetitle">引用于 <a class="profile-link highlight-default" href="#">minsheng</a> 在 2025-12-17, 下午7:41</div>应用我们的外星技术都可以消除. OBVIOUSLY ARE BETTER OFF, IF JAPANESE PEOPLE USE OUR ALIEN TECH. 因为有严重的代差和维度差, 绝大多数日本专业研究和医疗机构不理解我们在说什么和有什么. 
 
Here are several clinical trials and research efforts in Japan involving human cells—especially iPS (induced pluripotent stem cells) and related regenerative therapies. Many of these are registered as clinical studies or underway toward clinical trial status:
<hr data-start="273" data-end="276" />
<h2 data-start="278" data-end="340">🧬 1. iPS-derived exosome clinical research (2025–2026)</h2>
A clinical study is underway in Japan to evaluate safety and potential efficacy of iPS cell-derived exosomes (tiny cell-derived particles) for cognitive, muscle, and immune function decline related to aging. This is an interventional randomized double-blind, placebo-controlled trial involving participants aged 50–80. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://jrct.mhlw.go.jp/latest-detail/jRCT1033250410?utm_source=chatgpt.com" target="_blank" rel="noopener">JRCT</a>
<ul data-start="711" data-end="1006">
<li data-start="711" data-end="747">
Focus: iPS cell-derived exosomes
</li>
<li data-start="748" data-end="830">
Purpose: exploratory evaluation of effects on cognition/muscle/immune function
</li>
<li data-start="831" data-end="894">
Phase/Type: clinical research (not specified as drug phase)
</li>
<li data-start="895" data-end="940">
Timeline: Oct 2025 – Mar 2026 (estimated)
</li>
<li data-start="941" data-end="1006">
Subjects: 45 participants <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://jrct.mhlw.go.jp/latest-detail/jRCT1033250410?utm_source=chatgpt.com" target="_blank" rel="noopener">JRCT</a>
</li>
</ul>
<hr data-start="1008" data-end="1011" />
<h2 data-start="1013" data-end="1071">🫀 2. Heart muscle cell transplants using iPS cells</h2>
A Kyoto-based regenerative medicine startup iHeart Japan has conducted a clinical trial using a sheet of cardiac muscle cells derived from human iPS cells in a patient with dilated cardiomyopathy. Early reports indicate the patient has been discharged and is being monitored. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.japantimes.co.jp/news/2025/07/29/japan/science-health/ips-trial-heart-treatment/?utm_source=chatgpt.com" target="_blank" rel="noopener">The Japan Times</a>
<ul data-start="1403" data-end="1589">
<li data-start="1403" data-end="1440">
Focus: iPS-derived cardiac muscle
</li>
<li data-start="1441" data-end="1478">
Condition: dilated cardiomyopathy
</li>
<li data-start="1479" data-end="1589">
Institution: Tokyo Women’s Medical University Hospital / Kyoto startup <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.japantimes.co.jp/news/2025/07/29/japan/science-health/ips-trial-heart-treatment/?utm_source=chatgpt.com" target="_blank" rel="noopener">The Japan Times</a>
</li>
</ul>
<hr data-start="1591" data-end="1594" />
<h2 data-start="1596" data-end="1672">🧠 3. Parkinson’s disease and neurodegeneration iPS clinical research</h2>
Japanese research groups have conducted Phase I/II clinical studies transplanting iPS-derived dopaminergic neurons into patients with Parkinson’s disease, showing safety and feasibility in early trials. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a>
<ul data-start="1923" data-end="2106">
<li data-start="1923" data-end="1972">
Focus: PD regenerative therapy with iPS cells
</li>
<li data-start="1973" data-end="2011">
Phase: I/II (early clinical trial)
</li>
<li data-start="2012" data-end="2106">
Institution: Kyoto University (investigator-initiated) <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a>
</li>
</ul>
<hr data-start="2108" data-end="2111" />
<h2 data-start="2113" data-end="2167">👁️ 4. Retinal iPS/eye cell transplant research</h2>
Clinical research has been ongoing using human iPS cell-derived retinal pigment epithelium cells for wet age-related macular degeneration. Some early clinical research was initiated by institutions like Kobe City Eye Hospital. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a>
<ul data-start="2442" data-end="2578">
<li data-start="2442" data-end="2491">
Focus: retinal cells for macular degeneration
</li>
<li data-start="2492" data-end="2578">
Status: clinical research / early phase trials <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a>
</li>
</ul>
<hr data-start="2580" data-end="2583" />
<h2 data-start="2585" data-end="2645">🧬 5. Other iPS-derived cell therapies in development</h2>
According to a regulatory summary of Japanese clinical research:
<ul data-start="2712" data-end="3165">
<li data-start="2712" data-end="2760">
Cartilage cell transplants (knee injury)
</li>
<li data-start="2761" data-end="2835">
Allogeneic iPS cardiomyocytes (dilated and ischemic heart disease)
</li>
<li data-start="2836" data-end="2883">
Anti-GPC3 CAR-NK cells (ovarian cancer)
</li>
<li data-start="2884" data-end="2939">
Corneal endothelial cells (bullous keratopathy)
</li>
<li data-start="2940" data-end="3165">
Platelet-producing cells (thrombocytopenia) These are clinical research trials and early stages reflecting ongoing efforts toward therapeutic application of iPS-derived cells. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a>
</li>
</ul>
<hr data-start="3167" data-end="3170" />
<h2 data-start="3172" data-end="3227">📌 Background context (why Japan leads in this area)</h2>
Japan’s focus on iPS cell research stems from the pioneering work of Shinya Yamanaka, Nobel laureate for developing iPS technology, which has accelerated both basic science and clinical applications of human cells in regenerative medicine. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.jpma.or.jp/about_medicine/guide/med_qa/q50.html?utm_source=chatgpt.com" target="_blank" rel="noopener">JPMA</a>
The Japan Regenerative Medicine Project and research networks organized by AMED (Japan Agency for Medical Research and Development) support clinical translation of iPS/ES cell therapies from lab to patients. <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.amed.go.jp/program/list/index04_old.html?utm_source=chatgpt.com" target="_blank" rel="noopener">amed.go.jp</a>
<hr data-start="3768" data-end="3771" />
<h2 data-start="3773" data-end="3816">📍 Summary of Available Trials / Studies</h2>
<div class="TyagGW_tableContainer">
<div class="group TyagGW_tableWrapper flex w-fit flex-col-reverse">
<table class="w-fit min-w-(--thread-content-width)" data-start="3818" data-end="4500">
<thead data-start="3818" data-end="3855">
<tr data-start="3818" data-end="3855">
<th data-start="3818" data-end="3837" data-col-size="sm">Trial / Research</th>
<th data-start="3837" data-end="3845" data-col-size="sm">Focus</th>
<th data-start="3845" data-end="3855" data-col-size="sm">Status</th>
</tr>
</thead>
<tbody data-start="3894" data-end="4500">
<tr data-start="3894" data-end="4013">
<td data-start="3894" data-end="3922" data-col-size="sm">iPS-derived exosome trial</td>
<td data-start="3922" data-end="3953" data-col-size="sm">Aging biomarker intervention</td>
<td data-start="3953" data-end="4013" data-col-size="sm">Active 2025–2026 <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://jrct.mhlw.go.jp/latest-detail/jRCT1033250410?utm_source=chatgpt.com" target="_blank" rel="noopener">JRCT</a></td>
</tr>
<tr data-start="4014" data-end="4130">
<td data-start="4014" data-end="4051" data-col-size="sm">iHeart Japan heart cell transplant</td>
<td data-start="4051" data-end="4072" data-col-size="sm">iPS cardiac muscle</td>
<td data-start="4072" data-end="4130" data-col-size="sm">Reported trial <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.japantimes.co.jp/news/2025/07/29/japan/science-health/ips-trial-heart-treatment/?utm_source=chatgpt.com" target="_blank" rel="noopener">The Japan Times</a></td>
</tr>
<tr data-start="4131" data-end="4235">
<td data-start="4131" data-end="4158" data-col-size="sm">Parkinson’s cell therapy</td>
<td data-start="4158" data-end="4181" data-col-size="sm">Dopaminergic neurons</td>
<td data-start="4181" data-end="4235" data-col-size="sm">Phase I/II <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a></td>
</tr>
<tr data-start="4236" data-end="4355">
<td data-start="4236" data-end="4259" data-col-size="sm">Retinal cell therapy</td>
<td data-start="4259" data-end="4288" data-col-size="sm">Retinal pigment epithelium</td>
<td data-start="4288" data-end="4355" data-col-size="sm">Early clinical research <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a></td>
</tr>
<tr data-start="4356" data-end="4500">
<td data-start="4356" data-end="4392" data-col-size="sm">Multiple iPS/ES clinical research</td>
<td data-start="4392" data-end="4435" data-col-size="sm">Heart, cartilage, NK cells, cornea, etc.</td>
<td data-start="4435" data-end="4500" data-col-size="sm">Ongoing research list <a class="flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!" href="https://www.nihs.go.jp/kanren/iyaku/20230928-cbtp.pdf?utm_source=chatgpt.com" target="_blank" rel="noopener">National Institute of Health</a></td>
</tr>
</tbody>
</table>
</div>
</div>
<hr data-start="4502" data-end="4505" />
If you need direct registry links (e.g., jRCT or AMED trial pages) for any of these studies, let me know which one and I’ll pull them for you.</blockquote>

上传文件：
新增另一个文件...最大文件数量： 5 · 最大文件大小： 5,000 MB · 允许的文件类型： jpg,jpeg,gif,png,bmp,pdf,docx,xlsx,mp3,avi,png

取消